Absci Corporation

NasdaqGS ABSI

Absci Corporation Shareholders' Equity for the quarter ending September 30, 2024: USD 201.34 M

Absci Corporation Shareholders' Equity is USD 201.34 M for the quarter ending September 30, 2024, a 2.50% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Absci Corporation Shareholders' Equity for the quarter ending September 30, 2023 was USD 196.42 M, a -32.95% change year over year.
Absci Corporation Shareholders' Equity for the quarter ending September 30, 2022 was USD 292.94 M, a -24.50% change year over year.
Absci Corporation Shareholders' Equity for the quarter ending September 30, 2021 was USD 388.01 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: ABSI

Absci Corporation

CEO	Mr. Sean McClain
IPO Date	July 22, 2021
Location	United States
Headquarters	18105 SE Mill Plain Boulevard
Employees	155
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Fintech

Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Key trends

Past 5 years